Słowa kluczowe
trądzik odwrócony
trądzik pospolity
trą-
Jak cytować
Abstrakt
Dapson – czy zasadne jest stosowanie dapsonu jako opcji terapeutycznej w leczeniu trądziku zwykłego, trądziku różowatego oraz trądziku odwróconego? Petrosyan-Chrościcka P., Kwiek B. Wydział Medyczny, Uczelnia Łazarskiego, Warszawa, Klinika Ambroziak, Warszawa Dapsone is a chemical compound belonging to the sulfone group, primarily used as a first-line treatment for leprosy. Beyond this indication, it possesses a broad spectrum of antibacterial, antiparasitic, immunosuppressive/immunomodulatory, and anti-inflammatory properties, playing a key role in the management of numerous dermatological conditions. It is considered the first-line therapy for dermatitis herpetiformis and erythema elevatum diutinum. Additionally, it is employed in the treatment of other skin disorders such as bullous pemphigoid, mucous membrane pemphigoid, cutaneous lupus erythematosus, among others. This article discusses the therapeutic potential of dapsone in the treatment of acne vulgaris, rosacea, and hidradenitis suppurativa. Furthermore, an overview of dosing regimens used in other dermatological diseases is provided.
Bibliografia
Żychowska M., Batycka-Baran A., Szepietowski J. et al.: Dapsone – mechanism of action, safety of use and the role in the treatment of bullous pemphigoid according to current recommendations. Dermatol Rev 2016; 103(2): 176-184.
Yoshimura T., Matsushima K., Tanaka S. et al.: Purification of a human monocyte-derived neutrophil chemotactic factor Table 3. Oral and local treatment of various forms of acne, hidradenitis suppurativa and rosacea DiseaseOralTopical Acne vulgaris50–100 mg/day [10] 5% twice a day or 7.5% once a day [11]; apply a thin layer to lesions. FDA-approved. Acne fulminans 50–75 mg/day, rarely 100–200 mg/day (used in combination with prednisolone or isotretinoin, as per literature) Hidradenitis suppurativa 25–200 mg/day [3] Rosacea5% or 7.5% for 12 weeks [5,15]. Rosacea fulminans 100 mg/day with a 50 mg/day maintenance dose [18] Review of Medical Practice, 2025; Vol. XXXI, No. 372 that has peptide sequence similarity to other host defense cytokines. Proc Natl Acad Sci USA 1987; 84(24): 9233-9237.
Rabindranathnambi A., Jeevankumar B.: Dapsone in Hidra- denitis Suppurativa: A Systematic Review. Dermatol Ther (Heidelb) 2022; 12(2): 285-293.
Maymone M.B.C., Venkatesh S., Laughter M. et al.: Lepro- sy: Treatment and management of complications. J Am Acad Dermatol 2020; 83(1): 17-30.
Ghaoui N., Hanna E., Abbas O. et al.: Update on the use of dapsone in dermatology. Int J Dermatol 2020; 59(7): 787- 795.
Bieber T.: Dapson und Clofazimine: Wie und wozu?. In: Ple- wig G., Prinz J., eds. Fortschritte der praktischen Dermato- logie und Venerologie. Berlin, Heidelberg: Springer; 2003. 200-204.
Duan L., Chen L., Zhong S. et al.: Treatment of Bullous Sys- temic Lupus Erythematosus. J Immunol Res 2015; 2015: 167064.
Hrin M.L., Feldman S.R., Huang W.W.: Dapsone as corti- costeroid-sparing therapy for Sweet syndrome. J Am Acad Dermatol 2022; 86(3): 677-679.
Głuszak P., Beutler J., Kurkowska N. et al. Dapson in the Treatment of Pyoderma Gangrenosum: a Narrative Review. Dermatol Rev 2024; 111(5): 347-357.
Temiz S.A., Daye M.: Dapsone for the treatment of acne vul- garis: do the risks outweigh the benefits? Cutan Ocul Toxicol 2022; 41(1): 60-66.
Moore A.Y., Lain E.L., McMichael A. et al.: Once-daily Dap- sone 7.5% Gel for the Treatment of Acne Vulgaris in Pre- adolescent Patients: A Phase IV, Open-label, 12-week Study. J Clin Aesthet Dermatol 2021; 14(4): 43-48.
Hasanbeyzade S., Şenel E.: Comparison of topical dapso- ne + tretinoin and clindamycin + tretinoin combination in terms of effectiveness in the treatment of mild and moderate acne vulgaris: a retrospective analysis. Arch Dermatol Res 2025; 317(1): 272.
Gharib K., Samir M., Mohamed G. et al.: Efficacy and safety of topical spironolactone versus topical dapsone in the treatment of acne vulgaris. Arch Dermatol Res 2024; 316(10): 732.
Legal K., Misery L.: Isotretinoin-induced Acne Fulminans without Systemic Symptoms Treated Successfully with Oral Dapsone. Acta Derm Venereol 2020; 100(1): adv00036.
Gökşin Ş., İmren I.G., Kaçar N.: Efficacy of Topical Dapsone 5% Gel for the Treatment of Erythematotelangiectatic Rosa- cea: New Treatment Option with Old Drug. Dermatol Pract Concept 2024; 14(1): e2024034.
Özkoca D., Caf N.: The treatment efficacy of 7.5% dapsone gel in papulopustular rosacea: a prospective study. Cutaneo- us Ocul Toxicol 2024; 43(4): 405-409.
Merlo G., Cozzani E., Russo R. et al.: Dapsone for Unre- sponsive Granulomatous Rosacea. Am J Ther 2020; 27(3): e304-306.
Bormann G., Gaber G., Fischer M. et al.: Dapsone in rosa- cea fulminans. J Eur Acad Dermatol Venereol 2001; 15(5): 465-467. Paulina Petrosyan-Chrościcka declares no conflict of interests. Bartłomiej Kwiek reported serving as a clinical study investi- gator for AbbVie, Amgen Inc., Arcutis Biotherapeuthics, Almirall, Aslan, Bristol-Myers Squibb, Celdex Therapeutics, Celltrion, Der- mira, Galderma, Glenmark, Incyte, Janssen Pharmaceuticals, LEO Pharma, Novartis, Pfizer, Regeneron, Samsung.
Utwór dostępny jest na licencji Creative Commons Uznanie autorstwa – Użycie niekomercyjne – Na tych samych warunkach 4.0 Międzynarodowe.
Prawa autorskie (c) 2025 Review of Medical Practice